Lipren (Pravastatin Sodium)

Pravastatin sodium is indicated for disorders of lipid metabolism and for reducing cardiovascular risk.

• Hypercholesterolemia: lowers total and LDL cholesterol to target levels.
• Primary hypercholesterolemia: reduces elevated cholesterol in patients with genetic predisposition.
• Cardiovascular disease prevention: decreases the incidence of myocardial infarction and stroke in at‑risk populations.

• Pravastatin sodium competitively inhibits HMG‑CoA reductase, the key enzyme in hepatic cholesterol biosynthesis. This inhibition reduces intracellular cholesterol, leading to up‑regulation of LDL receptors on hepatocyte surfaces, which enhances clearance of circulating LDL‑cholesterol from the bloodstream.

Pravastatin sodium may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity.
• Gastrointestinal upset: includes dyspepsia, abdominal pain or constipation.
• Muscle pain or weakness: occasional myalgia without laboratory abnormalities.
• Nausea: transient feeling of queasiness.

Serious or Rare Side Effects

• Rhabdomyolysis: severe muscle breakdown with potential renal impairment.
• Elevated liver enzymes: indicates possible hepatic injury.
• Severe allergic reaction: includes rash, angioedema or anaphylaxis.
• Myopathy with marked CK elevation: requires immediate medical evaluation.

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor relevant parameters.

• Liver function monitoring: obtain baseline transaminases and repeat periodically.
• Renal function assessment: adjust use in patients with significant renal impairment.
• Muscle symptom evaluation: educate patients to report unexplained muscle pain or weakness.
• Drug interaction review: check concomitant medications that may increase statin exposure.
• Hypersensitivity avoidance: discontinue if signs of allergic reaction appear.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Pravastatin sodium can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Concurrent use with strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin) may increase statin levels.
• Combination with gemfibrozil or high‑dose niacin can raise the risk of myopathy.
• Co‑administration with cholestyramine or colestipol reduces pravastatin absorption.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect, requiring INR monitoring.
• Digoxin: potential increase in serum digoxin concentrations.
• Amiodarone: may modestly raise pravastatin plasma levels, warranting periodic CK checks.